메뉴 건너뛰기




Volumn 145, Issue , 2010, Pages 85-108

Receptor tyrosine kinase alterations in AML - Biology and therapy

Author keywords

[No Author keywords available]

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; 5,6,7,13 TETRAHYDRO 12 (3 HYDROXYPROPYL) 9 ISOPROPOXYMETHYLINDENO[2,1 A]PYRROLO[3,4 C]CARBAZOL 5(12H) ONE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; CYTARABINE; DASATINIB; DAUNORUBICIN; GROWTH FACTOR RECEPTOR BOUND PROTEIN 2; IMATINIB; LESTAURTINIB; MAMMALIAN TARGET OF RAPAMYCIN; MIDOSTAURIN; MITOGEN ACTIVATED PROTEIN KINASE; NILOTINIB; PHOSPHATIDYLINOSITOL 3 KINASE; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN KINASE B; PROTEIN SH2; PROTEIN TYROSINE KINASE; S6 KINASE; SEMAXANIB; STAT PROTEIN; SU 5614; SUNITINIB; TANDUTINIB; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; ANTINEOPLASTIC AGENT; CD135 ANTIGEN; FLT3 PROTEIN, HUMAN; ONCOPROTEIN; PROTEIN KINASE INHIBITOR; STEM CELL FACTOR RECEPTOR; TUMOR PROTEIN;

EID: 77956154092     PISSN: 09273042     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-0-387-69259-3_6     Document Type: Review
Times cited : (13)

References (182)
  • 2
    • 0033758958 scopus 로고    scopus 로고
    • FLT3 internal tandem duplication mutations in adult acute myeloid leukaemia define a high-risk group
    • Abu-Duhier FM, Goodeve AC, Wilson GA, et al. FLT3 internal tandem duplication mutations in adult acute myeloid leukaemia define a high-risk group. Br J Haematol. 2000;111:190-195.
    • (2000) Br J Haematol. , vol.111 , pp. 190-195
    • Abu-Duhier, F.M.1    Goodeve, A.C.2    Wilson, G.A.3
  • 3
    • 0027931013 scopus 로고
    • Genomic structure of the downstream part of the human FLT3 gene: Exon/intron structure conservation among genes encoding receptor tyrosine kinases (RTK) of subclass III
    • Agnes F, Shamoon B, Dina C, Rosnet O, Birnbaum D, Galibert F. Genomic structure of the downstream part of the human FLT3 gene: exon/intron structure conservation among genes encoding receptor tyrosine kinases (RTK) of subclass III. Gene. 1994;145:283-288.
    • (1994) Gene. , vol.145 , pp. 283-288
    • Agnes, F.1    Shamoon, B.2    Dina, C.3    Rosnet, O.4    Birnbaum, D.5    Galibert, F.6
  • 4
    • 0033485961 scopus 로고    scopus 로고
    • Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia
    • Aguayo A, Estey E, Kantarjian H, et al. Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia. Blood. 1999;94: 3717-3721.
    • (1999) Blood , vol.94 , pp. 3717-3721
    • Aguayo, A.1    Estey, E.2    Kantarjian, H.3
  • 5
    • 8844261773 scopus 로고    scopus 로고
    • Long-term survival estimates for imatinib versus interferon-alpha plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia
    • Anstrom KJ, Reed SD, Allen AS, Glendenning GA, Schulman KA. Long-term survival estimates for imatinib versus interferon-alpha plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia. Cancer. 2004;101:2584-2592.
    • (2004) Cancer. , vol.101 , pp. 2584-2592
    • Anstrom, K.J.1    Reed, S.D.2    Allen, A.S.3    Glendenning, G.A.4    Schulman, K.A.5
  • 6
    • 0013312329 scopus 로고    scopus 로고
    • Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification
    • Armstrong SA, Kung AL, Mabon ME, et al. Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification. Cancer Cell. 2003;3:173-183.
    • (2003) Cancer Cell. , vol.3 , pp. 173-183
    • Armstrong, S.A.1    Kung, A.L.2    Mabon, M.E.3
  • 7
    • 18544375333 scopus 로고    scopus 로고
    • MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia
    • Armstrong SA, Staunton JE, Silverman LB, et al. MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat Genet. 2002;30:41-47.
    • (2002) Nat Genet. , vol.30 , pp. 41-47
    • Armstrong, S.A.1    Staunton, J.E.2    Silverman, L.B.3
  • 8
    • 0032528499 scopus 로고    scopus 로고
    • C-kit activating mutations and mast cell proliferation in human leukemia
    • Beghini A, Larizza L, Cairoli R, Morra E. c-kit activating mutations and mast cell proliferation in human leukemia. Blood. 1998;92:701-702.
    • (1998) Blood , vol.92 , pp. 701-702
    • Beghini, A.1    Larizza, L.2    Cairoli, R.3    Morra, E.4
  • 9
    • 0034650957 scopus 로고    scopus 로고
    • C-kit mutations in core binding factor leukemias
    • Beghini A, Peterlongo P, Ripamonti CB, et al. C-kit mutations in core binding factor leukemias. Blood. 2000;95:726-727.
    • (2000) Blood , vol.95 , pp. 726-727
    • Beghini, A.1    Peterlongo, P.2    Ripamonti, C.B.3
  • 10
    • 3943068350 scopus 로고    scopus 로고
    • KIT activating mutations: Incidence in adult and pediatric acute myeloid leukemia, and identification of an internal tandem duplication
    • Beghini A, Ripamonti CB, Cairoli R, et al. KIT activating mutations: incidence in adult and pediatric acute myeloid leukemia, and identification of an internal tandem duplication. Haematologica. 2004;89:920-925.
    • (2004) Haematologica. , vol.89 , pp. 920-925
    • Beghini, A.1    Ripamonti, C.B.2    Cairoli, R.3
  • 11
    • 0034101453 scopus 로고    scopus 로고
    • Trisomy 4 leading to duplication of a mutated KIT allele in acute myeloid leukemia with mast cell involvement
    • Beghini A, Ripamonti CB, Castorina P, et al. Trisomy 4 leading to duplication of a mutated KIT allele in acute myeloid leukemia with mast cell involvement. Cancer Genet Cytogenet. 2000;119:26-31.
    • (2000) Cancer Genet Cytogenet. , vol.119 , pp. 26-31
    • Beghini, A.1    Ripamonti, C.B.2    Castorina, P.3
  • 12
    • 10844290923 scopus 로고    scopus 로고
    • Activating mutations of the noonan syndromeassociated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia
    • Bentires-Alj M, Paez JG, David FS, et al. Activating mutations of the noonan syndromeassociated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia. Cancer Res. 2004;64:8816-8820.
    • (2004) Cancer Res. , vol.64 , pp. 8816-8820
    • Bentires-Alj, M.1    Paez, J.G.2    David, F.S.3
  • 13
    • 0035203382 scopus 로고    scopus 로고
    • Regulation of constitutive STAT5 phosphorylation in acute myeloid leukemia blasts
    • Birkenkamp KU, Geugien M, Lemmink HH, Kruijer W, Vellenga E. Regulation of constitutive STAT5 phosphorylation in acute myeloid leukemia blasts. Leukemia. 2001; 15:1923-1931.
    • (2001) Leukemia. , vol.15 , pp. 1923-1931
    • Birkenkamp, K.U.1    Geugien, M.2    Lemmink, H.H.3    Kruijer, W.4    Vellenga, E.5
  • 14
    • 0035902180 scopus 로고    scopus 로고
    • Oncogenic kinase signalling
    • Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature. 2001;411:355-365.
    • (2001) Nature. , vol.411 , pp. 355-365
    • Blume-Jensen, P.1    Hunter, T.2
  • 15
    • 0024376173 scopus 로고
    • Ras oncogenes in human cancer: A review
    • Bos JL. Ras oncogenes in human cancer: a review. Cancer Res. 1989;49:4682-4689.
    • (1989) Cancer Res. , vol.49 , pp. 4682-4689
    • Bos, J.L.1
  • 16
    • 0025744150 scopus 로고
    • Loss of both CSF1R (FMS) alleles in patients with myelodysplasia and a chromosome 5 deletion
    • Boultwood J, Rack K, Kelly S, et al. Loss of both CSF1R (FMS) alleles in patients with myelodysplasia and a chromosome 5 deletion. Proc Natl Acad Sci USA. 1991;88:6176-6180.
    • (1991) Proc Natl Acad Sci USA. , vol.88 , pp. 6176-6180
    • Boultwood, J.1    Rack, K.2    Kelly, S.3
  • 17
    • 24744449132 scopus 로고    scopus 로고
    • RAS mutation in acute myeloid leukemia is associated with distinct cytogenetic subgroups but does not influence outcome in patients younger than 60 years
    • Bowen DT, Frew ME, Hills R, et al. RAS mutation in acute myeloid leukemia is associated with distinct cytogenetic subgroups but does not influence outcome in patients younger than 60 years. Blood. 2005;106:2113-2119.
    • (2005) Blood , vol.106 , pp. 2113-2119
    • Bowen, D.T.1    Frew, M.E.2    Hills, R.3
  • 18
    • 27544450742 scopus 로고    scopus 로고
    • Constitutive activation of Akt by Flt3 internal tandem duplications is necessary for increased survival, proliferation, and myeloid transformation
    • Brandts CH, Sargin B, Rode M, et al. Constitutive activation of Akt by Flt3 internal tandem duplications is necessary for increased survival, proliferation, and myeloid transformation. Cancer Res. 2005;65:9643-9650.
    • (2005) Cancer Res. , vol.65 , pp. 9643-9650
    • Brandts, C.H.1    Sargin, B.2    Rode, M.3
  • 19
    • 33646432204 scopus 로고    scopus 로고
    • Prognostic impact of c-KIT mutations in core binding factor leukemias. An Italian retrospective study
    • In press
    • Cairoli R, Beghini A, Grillo G, et al. Prognostic impact of c-KIT mutations in core binding factor leukemias. An Italian retrospective study. Blood. 2006. In press.
    • (2006) Blood
    • Cairoli, R.1    Beghini, A.2    Grillo, G.3
  • 20
    • 13844275633 scopus 로고    scopus 로고
    • Imatinib mesylate in the treatment of Core Binding Factor leukemias withKIT mutations. A report of three cases
    • Cairoli R, Beghini A, Morello E, et al. Imatinib mesylate in the treatment of Core Binding Factor leukemias withKIT mutations. A report of three cases. Leuk Res. 2005;29:397-400.
    • (2005) Leuk Res. , vol.29 , pp. 397-400
    • Cairoli, R.1    Beghini, A.2    Morello, E.3
  • 21
    • 0037330478 scopus 로고    scopus 로고
    • C-Kit point mutations in core binding factor leukemias: Correlation with white blood cell count and the white blood cell index
    • Cairoli R, Grillo G, Beghini A, et al. C-Kit point mutations in core binding factor leukemias: correlation with white blood cell count and the white blood cell index. Leukemia. 2003;17:471-472.
    • (2003) Leukemia. , vol.17 , pp. 471-472
    • Cairoli, R.1    Grillo, G.2    Beghini, A.3
  • 22
    • 21744440587 scopus 로고    scopus 로고
    • Prognostic implication of FLT3 and Ras gene mutations in patients with acute promyelocytic leukemia (APL): A retrospective study from the European APL Group
    • Callens C, Chevret S, Cayuela JM, et al. Prognostic implication of FLT3 and Ras gene mutations in patients with acute promyelocytic leukemia (APL): a retrospective study from the European APL Group. Leukemia. 2005;19:1153-1160.
    • (2005) Leukemia. , vol.19 , pp. 1153-1160
    • Callens, C.1    Chevret, S.2    Cayuela, J.M.3
  • 23
    • 28444437728 scopus 로고    scopus 로고
    • Extracellular KIT receptor mutants, commonly found in core binding factor AML, are constitutively active and respond to imatinib mesylate
    • Cammenga J, Horn S, Bergholz U, et al. Extracellular KIT receptor mutants, commonly found in core binding factor AML, are constitutively active and respond to imatinib mesylate. Blood. 2005;106:3958-3961.
    • (2005) Blood , vol.106 , pp. 3958-3961
    • Cammenga, J.1    Horn, S.2    Bergholz, U.3
  • 24
    • 0038170400 scopus 로고    scopus 로고
    • Incidence and prognosis of c-KIT and FLT3 mutations in core binding factor (CBF) acute myeloid leukaemias
    • Care RS, Valk PJ, Goodeve AC, et al. Incidence and prognosis of c-KIT and FLT3 mutations in core binding factor (CBF) acute myeloid leukaemias. Br J Haematol. 2003; 121:775-777.
    • (2003) Br J Haematol. , vol.121 , pp. 775-777
    • Care, R.S.1    Valk, P.J.2    Goodeve, A.C.3
  • 25
    • 0029966854 scopus 로고    scopus 로고
    • The TEL/plateletderived growth factor beta receptor (PDGF beta R) fusion in chronic myelomonocytic leukemia is a transforming protein that self-associates and activates PDGF beta R kinase-dependent signaling pathways
    • Carroll M, Tomasson MH, Barker GF, Golub TR, Gilliland DG. The TEL/plateletderived growth factor beta receptor (PDGF beta R) fusion in chronic myelomonocytic leukemia is a transforming protein that self-associates and activates PDGF beta R kinase-dependent signaling pathways. Proc Natl Acad Sci USA. 1996;93:14845-14850.
    • (1996) Proc Natl Acad Sci USA. , vol.93 , pp. 14845-14850
    • Carroll, M.1    Tomasson, M.H.2    Barker, G.F.3    Golub, T.R.4    Gilliland, D.G.5
  • 26
    • 0027286420 scopus 로고
    • N-ras mutation in acute myeloid leukemia: Incidence, prognostic significance and value as a marker of minimal residual disease
    • Casey G, Rudzki Z, Roberts M, Hutchins C, Juttner C. N-ras mutation in acute myeloid leukemia: incidence, prognostic significance and value as a marker of minimal residual disease. Pathology. 1993;25:57-62.
    • (1993) Pathology. , vol.25 , pp. 57-62
    • Casey, G.1    Rudzki, Z.2    Roberts, M.3    Hutchins, C.4    Juttner, C.5
  • 27
    • 28544448340 scopus 로고    scopus 로고
    • Mutations of genes in the receptor tyrosine kinase (RTK)/RAS-BRAF signal transduction pathway in therapyrelated myelodysplasia and acute myeloid leukemia
    • Christiansen DH, Andersen MK, Desta F, Pedersen-Bjergaard J. Mutations of genes in the receptor tyrosine kinase (RTK)/RAS-BRAF signal transduction pathway in therapyrelated myelodysplasia and acute myeloid leukemia. Leukemia. 2005;19:2232-2240.
    • (2005) Leukemia. , vol.19 , pp. 2232-2240
    • Christiansen, D.H.1    Andersen, M.K.2    Desta, F.3    Pedersen-Bjergaard, J.4
  • 28
    • 0344987881 scopus 로고    scopus 로고
    • A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome
    • Cools J, DeAngelo DJ, Gotlib J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med. 2003;348:1201-1214.
    • (2003) N Engl J Med. , vol.348 , pp. 1201-1214
    • Cools, J.1    Deangelo, D.J.2    Gotlib, J.3
  • 29
    • 33645473956 scopus 로고    scopus 로고
    • Detection of the FIP1L1-PDGFRA fusion in idiopathic hypereosinophilic syndrome and chronic eosinophilic leukemia
    • Cools J, Stover EH, Gilliland DG. Detection of the FIP1L1-PDGFRA fusion in idiopathic hypereosinophilic syndrome and chronic eosinophilic leukemia. Methods Mol Med. 2006;125:177-187.
    • (2006) Methods Mol Med. , vol.125 , pp. 177-187
    • Cools, J.1    Stover, E.H.2    Gilliland, D.G.3
  • 30
    • 0346249716 scopus 로고    scopus 로고
    • The FIP1L1-PDGFRalpha kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia
    • Cools J, Stover EH, Wlodarska I, Marynen P, Gilliland DG. The FIP1L1-PDGFRalpha kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia. Curr Opin Hematol. 2004;11:51-57.
    • (2004) Curr Opin Hematol. , vol.11 , pp. 51-57
    • Cools, J.1    Stover, E.H.2    Wlodarska, I.3    Marynen, P.4    Gilliland, D.G.5
  • 31
    • 24144487571 scopus 로고    scopus 로고
    • Phase II evaluation of the tyrosine kinase inhibitor MLN518 in patients with acute myeloid leukemia (AML) bearing a FLT3 internal tandem duplication (ITD) mutation
    • De Angelo DJ, Stone RM, Heaney ML, et al. Phase II evaluation of the tyrosine kinase inhibitor MLN518 in patients with acute myeloid leukemia (AML) bearing a FLT3 internal tandem duplication (ITD) mutation. Blood. 2004;104:1792a.
    • (2004) Blood , vol.104 , pp. 1792
    • De Angelo, D.J.1    Stone, R.M.2    Heaney, M.L.3
  • 32
    • 0025892781 scopus 로고
    • Alterations in CSF-1 receptor expression and protein tyrosine phosphorylation in autonomous mutants of a CSF-1 dependent macrophage cell line
    • Dello Sbarba P, Pollard JW, Stanley ER. Alterations in CSF-1 receptor expression and protein tyrosine phosphorylation in autonomous mutants of a CSF-1 dependent macrophage cell line. Growth Factors. 1991;5:75-85.
    • (1991) Growth Factors. , vol.5 , pp. 75-85
    • Dello Sbarba, P.1    Pollard, J.W.2    Stanley, E.R.3
  • 33
    • 0033987746 scopus 로고    scopus 로고
    • Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia
    • Druker BJ, Lydon NB. Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest. 2000;105:3-7.
    • (2000) J Clin Invest. , vol.105 , pp. 3-7
    • Druker, B.J.1    Lydon, N.B.2
  • 34
    • 0035810142 scopus 로고    scopus 로고
    • Activity of a specific inhibitor of the BCRABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome
    • Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCRABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med. 2001;344:1038-1042.
    • (2001) N Engl J Med. , vol.344 , pp. 1038-1042
    • Druker, B.J.1    Sawyers, C.L.2    Kantarjian, H.3
  • 35
    • 0023880245 scopus 로고
    • Analysis of RAS gene mutations in acute myeloid leukemia by polymerase chain reaction and oligonucleotide probes
    • Farr CJ, Saiki RK, Erlich HA, McCormick F, Marshall CJ. Analysis of RAS gene mutations in acute myeloid leukemia by polymerase chain reaction and oligonucleotide probes. Proc Natl Acad Sci USA. 1988;85:1629-1633.
    • (1988) Proc Natl Acad Sci USA. , vol.85 , pp. 1629-1633
    • Farr, C.J.1    Saiki, R.K.2    Erlich, H.A.3    McCormick, F.4    Marshall, C.J.5
  • 36
    • 0026086464 scopus 로고
    • Increased methylation of the c-fms protooncogene in acute myelomonocytic leukemias
    • Felgner J, Kreipe H, Heidorn K, et al. Increased methylation of the c-fms protooncogene in acute myelomonocytic leukemias. Pathobiology. 1991;59:293-298.
    • (1991) Pathobiology. , vol.59 , pp. 293-298
    • Felgner, J.1    Kreipe, H.2    Heidorn, K.3
  • 37
    • 0000796896 scopus 로고    scopus 로고
    • Constitutive activation of FLT3 in acute myeloid leukaemia and its consequences for growth of 32D cells
    • Fenski R, Flesch K, Serve S, et al. Constitutive activation of FLT3 in acute myeloid leukaemia and its consequences for growth of 32D cells. Br JHaematol. 2000;108:322-330.
    • (2000) Br JHaematol. , vol.108 , pp. 322-330
    • Fenski, R.1    Flesch, K.2    Serve, S.3
  • 38
    • 0142175216 scopus 로고    scopus 로고
    • An innovative single dose clinical study shows potent inhibition of FLT3 phosphorylation by SU11248 in vivo: A clinical and pharmacodynamic study in AML patients
    • Foran J, OFarrell AM, Fiedler W, et al. An innovative single dose clinical study shows potent inhibition of FLT3 phosphorylation by SU11248 in vivo: a clinical and pharmacodynamic study in AML patients. Blood. 2002;100:2196a.
    • (2002) Blood , vol.100 , pp. 2196
    • Foran, J.1    Ofarrell, A.M.2    Fiedler, W.3
  • 39
    • 0141500351 scopus 로고    scopus 로고
    • A phase i study of repeated oral dosing with SU11248 for the treatment of patients with acute myeloid leukemia who have failed, or are not eligible for conventional chemotherapy
    • Foran J, Paquette R, Cooper M, et al. A phase I study of repeated oral dosing with SU11248 for the treatment of patients with acute myeloid leukemia who have failed, or are not eligible for conventional chemotherapy. Blood. 2002;100:2195a.
    • (2002) Blood , vol.100 , pp. 2195
    • Foran, J.1    Paquette, R.2    Cooper, M.3
  • 40
    • 0023262990 scopus 로고
    • Detection of high incidence of K-ras oncogenes during human colon tumorigenesis
    • Forrester K, Almoguera C, Han K, Grizzle WE, Perucho M. Detection of high incidence of K-ras oncogenes during human colon tumorigenesis. Nature. 1987;327:298-303.
    • (1987) Nature. , vol.327 , pp. 298-303
    • Forrester, K.1    Almoguera, C.2    Han, K.3    Grizzle, W.E.4    Perucho, M.5
  • 41
    • 0037114829 scopus 로고    scopus 로고
    • Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: A study of the AML Study Group Ulm
    • Frohling S, Schlenk RF, Breitruck J, et al. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. Blood. 2002;100:4372-4380.
    • (2002) Blood , vol.100 , pp. 4372-4380
    • Frohling, S.1    Schlenk, R.F.2    Breitruck, J.3
  • 42
    • 0027359443 scopus 로고
    • Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product
    • Furitsu T, Tsujimura T, Tono T, et al. Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. J Clin Invest. 1993;92:1736-1744.
    • (1993) J Clin Invest. , vol.92 , pp. 1736-1744
    • Furitsu, T.1    Tsujimura, T.2    Tono, T.3
  • 43
    • 33645685429 scopus 로고    scopus 로고
    • Identification of potent and selective inhibitors of PDGF receptor autophosphorylation
    • Furuta T, Sakai T, Senga T, et al. Identification of potent and selective inhibitors of PDGF receptor autophosphorylation. J Med Chem. 2006;49:2186-2192.
    • (2006) J Med Chem. , vol.49 , pp. 2186-2192
    • Furuta, T.1    Sakai, T.2    Senga, T.3
  • 44
    • 0029134556 scopus 로고
    • Multi-level effects of flt3 ligand on human hematopoiesis: Expansion of putative stem cells and proliferation of granulomonocytic progenitors/monocytic precursors
    • Gabbianelli M, Pelosi E, Montesoro E, et al. Multi-level effects of flt3 ligand on human hematopoiesis: expansion of putative stem cells and proliferation of granulomonocytic progenitors/monocytic precursors. Blood. 1995;86:1661-1670.
    • (1995) Blood , vol.86 , pp. 1661-1670
    • Gabbianelli, M.1    Pelosi, E.2    Montesoro, E.3
  • 45
    • 0032989226 scopus 로고    scopus 로고
    • C-kit proto-oncogene exon 8 in-frame deletion plus insertion mutations in acute myeloid leukaemia
    • Gari M, Goodeve A, Wilson G, et al. c-kit proto-oncogene exon 8 in-frame deletion plus insertion mutations in acute myeloid leukaemia. Br J Haematol. 1999;105:894-900.
    • (1999) Br J Haematol. , vol.105 , pp. 894-900
    • Gari, M.1    Goodeve, A.2    Wilson, G.3
  • 46
    • 24144448140 scopus 로고    scopus 로고
    • Phase 1 study of PKC412, an oral FLT3 kinase inhibitor, in sequential and concomitant combinations with daunorubicin and cytarabine (DA) induction and high-dose cytarabine consolidation in newly diagnosed patients with AML
    • Giles F, Schiffer C, Kantarjian H, et al. Phase 1 study of PKC412, an oral FLT3 kinase inhibitor, in sequential and concomitant combinations with daunorubicin and cytarabine (DA) induction and high-dose cytarabine consolidation in newly diagnosed patients with AML. Blood. 2004;104:262a.
    • (2004) Blood , vol.104 , pp. 262
    • Giles, F.1    Schiffer, C.2    Kantarjian, H.3
  • 47
    • 0043245991 scopus 로고    scopus 로고
    • SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes
    • Giles FJ, Stopeck AT, Silverman LR, et al. SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes. Blood. 2003;102:795-801.
    • (2003) Blood , vol.102 , pp. 795-801
    • Giles, F.J.1    Stopeck, A.T.2    Silverman, L.R.3
  • 48
    • 0034254273 scopus 로고    scopus 로고
    • A repressor sequence in the juxtamembrane domain of Flt-1 (VEGFR-1) constitutively inhibits vascular endothelial growth factor-dependent phosphatidylinositol 30-kinase activation and endothelial cell migration
    • Gille H, Kowalski J, Yu L, et al. A repressor sequence in the juxtamembrane domain of Flt-1 (VEGFR-1) constitutively inhibits vascular endothelial growth factor-dependent phosphatidylinositol 30-kinase activation and endothelial cell migration. Embo J. 2000; 19:4064-4073.
    • (2000) Embo J. , vol.19 , pp. 4064-4073
    • Gille, H.1    Kowalski, J.2    Yu, L.3
  • 49
    • 26944447953 scopus 로고    scopus 로고
    • Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia
    • Goemans BF, Zwaan CM, Miller M, et al.Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia. Leukemia. 2005;19: 1536-1542.
    • (2005) Leukemia. , vol.19 , pp. 1536-1542
    • Goemans, B.F.1    Zwaan, C.M.2    Miller, M.3
  • 50
    • 0028224348 scopus 로고
    • Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation
    • Golub TR, Barker GF, Lovett M, Gilliland DG. Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell. 1994;77:307-316.
    • (1994) Cell. , vol.77 , pp. 307-316
    • Golub, T.R.1    Barker, G.F.2    Lovett, M.3    Gilliland, D.G.4
  • 51
    • 1842474941 scopus 로고    scopus 로고
    • The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: Implications for diagnosis, classification, and management
    • Gotlib J, Cools J, Malone JM, 3rd, Schrier SL, Gilliland DG, Coutre SE. The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management. Blood. 2004;103:2879-2891.
    • (2004) Blood , vol.103 , pp. 2879-2891
    • Gotlib, J.1    Cools, J.2    Malone III, J.M.3    Schrier, S.L.4    Gilliland, D.G.5    Coutre, S.E.6
  • 52
    • 0842310394 scopus 로고    scopus 로고
    • The structural basis for autoinhibition of FLT3 by the juxtamembrane domain
    • Griffith J, Black J, Faerman C, et al. The structural basis for autoinhibition of FLT3 by the juxtamembrane domain. Mol Cell. 2004;13:169-178.
    • (2004) Mol Cell. , vol.13 , pp. 169-178
    • Griffith, J.1    Black, J.2    Faerman, C.3
  • 53
    • 20444402664 scopus 로고    scopus 로고
    • FLT3-ITD and tyrosine kinase domain mutants induce 2 distinct phenotypes in a murine bone marrow transplantation model
    • Grundler R, Miething C, Thiede C, Peschel C, Duyster J. FLT3-ITD and tyrosine kinase domain mutants induce 2 distinct phenotypes in a murine bone marrow transplantation model. Blood. 2005;105:4792-4799.
    • (2005) Blood , vol.105 , pp. 4792-4799
    • Grundler, R.1    Miething, C.2    Thiede, C.3    Peschel, C.4    Duyster, J.5
  • 54
    • 0034598830 scopus 로고    scopus 로고
    • Tandem-duplicated Flt3 constitutively activates STAT5 andMAPkinase and introduces autonomous cell growth in IL-3-dependent cell lines
    • Hayakawa F, Towatari M, Kiyoi H, et al. Tandem-duplicated Flt3 constitutively activates STAT5 andMAPkinase and introduces autonomous cell growth in IL-3-dependent cell lines. Oncogene. 2000;19:624-631.
    • (2000) Oncogene. , vol.19 , pp. 624-631
    • Hayakawa, F.1    Towatari, M.2    Kiyoi, H.3
  • 55
    • 0012765842 scopus 로고    scopus 로고
    • A"first in man" study of the safety and PK/PD of an oral FLT3 inhibitor (MLN518) in patients with AML or high risk myelodyspsia
    • Heinrich MC, Druker BJ, Curtin PT, et al.A"first in man" study of the safety and PK/PD of an oral FLT3 inhibitor (MLN518) in patients with AML or high risk myelodyspsia. Blood. 2002;100:1305a.
    • (2002) Blood , vol.100
    • Heinrich, M.C.1    Druker, B.J.2    Curtin, P.T.3
  • 56
    • 0034254249 scopus 로고    scopus 로고
    • Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor
    • Heinrich MC, Griffith DJ, Druker BJ, Wait CL, Ott KA, Zigler AJ. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood. 2000;96:925-932.
    • (2000) Blood , vol.96 , pp. 925-932
    • Heinrich, M.C.1    Griffith, D.J.2    Druker, B.J.3    Wait, C.L.4    Ott, K.A.5    Zigler, A.J.6
  • 57
    • 0036850514 scopus 로고    scopus 로고
    • Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy
    • Hochhaus A, Kreil S, Corbin AS, et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia. 2002;16:2190-2196.
    • (2002) Leukemia. , vol.16 , pp. 2190-2196
    • Hochhaus, A.1    Kreil, S.2    Corbin, A.S.3
  • 58
    • 10744229080 scopus 로고    scopus 로고
    • Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia
    • Hughes TP, Kaeda J, Branford S, et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med. 2003;349:1423-1432.
    • (2003) N Engl J Med. , vol.349 , pp. 1423-1432
    • Hughes, T.P.1    Kaeda, J.2    Branford, S.3
  • 59
    • 0032931560 scopus 로고    scopus 로고
    • Internal tandem duplication of the FLT3 gene and clinical evaluation in childhood acute myeloid leukemia. The childrens cancer and leukemia study group, Japan
    • Iwai T, Yokota S, Nakao M, et al. Internal tandem duplication of the FLT3 gene and clinical evaluation in childhood acute myeloid leukemia. The Childrens Cancer and Leukemia Study Group, Japan. Leukemia. 1999;13:38-43.
    • (1999) Leukemia. , vol.13 , pp. 38-43
    • Iwai, T.1    Yokota, S.2    Nakao, M.3
  • 60
    • 0011134388 scopus 로고
    • RAS gene mutations in acute and chronic myelocytic leukemias, chronic myeloproliferative disorders, and myelodysplastic syndromes
    • Janssen JW, Steenvoorden AC, Lyons J, et al. RAS gene mutations in acute and chronic myelocytic leukemias, chronic myeloproliferative disorders, and myelodysplastic syndromes. Proc Natl Acad Sci USA. 1987;84:9228-9232.
    • (1987) Proc Natl Acad Sci USA. , vol.84 , pp. 9228-9232
    • Janssen, J.W.1    Steenvoorden, A.C.2    Lyons, J.3
  • 61
    • 0035383789 scopus 로고    scopus 로고
    • Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: A phase 1 clinical-laboratory correlative trial
    • Karp JE, Lancet JE, Kaufmann SH, et al. Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial. Blood. 2001;97:3361-3369.
    • (2001) Blood , vol.97 , pp. 3361-3369
    • Karp, J.E.1    Lancet, J.E.2    Kaufmann, S.H.3
  • 62
    • 34248210118 scopus 로고    scopus 로고
    • Development of the farnesyltransferase inhibitor tipifarnib for therapy of hematologic malignancies
    • Karp JE, Lancet JE. Development of the farnesyltransferase inhibitor tipifarnib for therapy of hematologic malignancies. Fut Oncol. 2005;1:719-731.
    • (2005) Fut Oncol. , vol.1 , pp. 719-731
    • Karp, J.E.1    Lancet, J.E.2
  • 63
    • 29244485567 scopus 로고    scopus 로고
    • Targeting the process of farnesylation for therapy of hematologic malignancies
    • Karp JE, Lancet JE. Targeting the process of farnesylation for therapy of hematologic malignancies. Curr Mol Med. 2005;5:643-652.
    • (2005) Curr Mol Med. , vol.5 , pp. 643-652
    • Karp, J.E.1    Lancet, J.E.2
  • 64
    • 0037062350 scopus 로고    scopus 로고
    • PML/RARalpha and FLT3-ITD induce an APL-like disease in a mouse model
    • Kelly LM, Kutok JL, Williams IR, et al. PML/RARalpha and FLT3-ITD induce an APL-like disease in a mouse model. Proc Natl Acad Sci USA. 2002;99:8283-8288.
    • (2002) Proc Natl Acad Sci USA. , vol.99 , pp. 8283-8288
    • Kelly, L.M.1    Kutok, J.L.2    Williams, I.R.3
  • 65
    • 0036093475 scopus 로고    scopus 로고
    • FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model
    • Kelly LM, Liu Q, Kutok JL, Williams IR, Boulton CL, Gilliland DG. FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model. Blood. 2002;99: 310-318.
    • (2002) Blood , vol.99 , pp. 310-318
    • Kelly, L.M.1    Liu, Q.2    Kutok, J.L.3    Williams, I.R.4    Boulton, C.L.5    Gilliland, D.G.6
  • 66
    • 0013102301 scopus 로고    scopus 로고
    • CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML)
    • Kelly LM, Yu J, Boulton CL, et al. CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML). Caner Cell. 2002.
    • (2002) Caner Cell.
    • Kelly, L.M.1    Yu, J.2    Boulton, C.L.3
  • 67
    • 19944427369 scopus 로고    scopus 로고
    • Identification of a novel activating mutation (Y842C) within the activation loop of FLT3 in patients with acute myeloid leukemia (AML)
    • Kindler T, Breitenbuecher F, Kasper S, et al. Identification of a novel activating mutation (Y842C) within the activation loop of FLT3 in patients with acute myeloid leukemia (AML). Blood. 2005;105:335-340.
    • (2005) Blood , vol.105 , pp. 335-340
    • Kindler, T.1    Breitenbuecher, F.2    Kasper, S.3
  • 68
    • 0028959163 scopus 로고
    • Constitutively activating mutations of c-kit receptor tyrosine kinase confer factor-independent growth and tumorigenicity of factordependent hematopoietic cell lines
    • Kitayama H, Kanakura Y, Furitsu T, et al. Constitutively activating mutations of c-kit receptor tyrosine kinase confer factor-independent growth and tumorigenicity of factordependent hematopoietic cell lines. Blood. 1995;85:790-798.
    • (1995) Blood , vol.85 , pp. 790-798
    • Kitayama, H.1    Kanakura, Y.2    Furitsu, T.3
  • 69
    • 0033134792 scopus 로고    scopus 로고
    • Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia
    • Kiyoi H, Naoe T, Nakano Y, et al. Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood. 1999;93:3074-3080.
    • (1999) Blood , vol.93 , pp. 3074-3080
    • Kiyoi, H.1    Naoe, T.2    Nakano, Y.3
  • 70
    • 0037061747 scopus 로고    scopus 로고
    • Mechanism of constitutive activation of FLT3 with internal tandem duplication in the juxtamembrane domain
    • Kiyoi H, Ohno R, Ueda R, Saito H, Naoe T. Mechanism of constitutive activation of FLT3 with internal tandem duplication in the juxtamembrane domain. Oncogene. 2002;21:2555-2563.
    • (2002) Oncogene. , vol.21 , pp. 2555-2563
    • Kiyoi, H.1    Ohno, R.2    Ueda, R.3    Saito, H.4    Naoe, T.5
  • 71
    • 0031686409 scopus 로고    scopus 로고
    • Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product
    • Kiyoi H, Towatari M, Yokota S, et al. Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product. Leukemia. 1998;12:1333-1337.
    • (1998) Leukemia. , vol.12 , pp. 1333-1337
    • Kiyoi, H.1    Towatari, M.2    Yokota, S.3
  • 72
    • 17044435979 scopus 로고    scopus 로고
    • KIT exon 8 mutations associated with core-binding factor (CBF)-acute myeloid leukemia (AML) cause hyperactivation of the receptor in response to stem cell factor
    • Kohl TM, Schnittger S, Ellwart JW,Hiddemann W, Spiekermann K.KIT exon 8 mutations associated with core-binding factor (CBF)-acute myeloid leukemia (AML) cause hyperactivation of the receptor in response to stem cell factor. Blood. 2005;105:3319-3321.
    • (2005) Blood , vol.105 , pp. 3319-3321
    • Kohl, T.M.1    Schnittger, S.2    Ellwart, J.W.3    Hiddemann, W.4    Spiekermann, K.5
  • 73
    • 0032757551 scopus 로고    scopus 로고
    • Prognostic value of internal tandem duplication of the FLT3 gene in childhood acute myelogenous leukemia
    • Kondo M, Horibe K, Takahashi Y, et al. Prognostic value of internal tandem duplication of the FLT3 gene in childhood acute myelogenous leukemia. Med Pediatr Oncol. 1999;33:525-529.
    • (1999) Med Pediatr Oncol. , vol.33 , pp. 525-529
    • Kondo, M.1    Horibe, K.2    Takahashi, Y.3
  • 74
    • 0035885955 scopus 로고    scopus 로고
    • The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: Analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials
    • Kottaridis PD, Gale RE, Frew ME, et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood. 2001;98:1752-1759.
    • (2001) Blood , vol.98 , pp. 1752-1759
    • Kottaridis, P.D.1    Gale, R.E.2    Frew, M.E.3
  • 75
    • 0036785393 scopus 로고    scopus 로고
    • Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia: Implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibitors
    • Kottaridis PD, Gale RE, Langabeer SE, Frew ME, Bowen DT, Linch DC. Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia: implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibitors. Blood. 2002;100:2393-2398
    • (2002) Blood , vol.100 , pp. 2393-2398
    • Kottaridis, P.D.1    Gale, R.E.2    Langabeer, S.E.3    Frew, M.E.4    Bowen, D.T.5    Linch, D.C.6
  • 76
    • 0027155193 scopus 로고
    • Clonal analysis of multiple point mutations in the N-ras gene in patients with acute myeloid leukemia
    • Kubo K, Naoe T, Kiyoi H, et al. Clonal analysis of multiple point mutations in the N-ras gene in patients with acute myeloid leukemia. Jpn J Cancer Res. 1993;84:379-387.
    • (1993) Jpn J Cancer Res. , vol.84 , pp. 379-387
    • Kubo, K.1    Naoe, T.2    Kiyoi, H.3
  • 77
    • 29244466856 scopus 로고    scopus 로고
    • AML1-ETO needs a partner: New insights into the pathogenesis of t(8;21) leukemia
    • Kuchenbauer F, Feuring-Buske M, Buske C. AML1-ETO needs a partner: new insights into the pathogenesis of t(8;21) leukemia. Cell Cycle. 2005;4:1716-1718.
    • (2005) Cell Cycle. , vol.4 , pp. 1716-1718
    • Kuchenbauer, F.1    Feuring-Buske, M.2    Buske, C.3
  • 78
    • 7244236503 scopus 로고    scopus 로고
    • Gene Expression Profiles at Diagnosis in de novo Childhood AML Patients Identify FLT3 Mutations with Good Clinical Outcomes
    • Lacayo NJ, Meshinchi S, Kinnunen P, et al. Gene Expression Profiles at Diagnosis in de novo Childhood AML Patients Identify FLT3 Mutations with Good Clinical Outcomes. Blood. 2004.
    • (2004) Blood
    • Lacayo, N.J.1    Meshinchi, S.2    Kinnunen, P.3
  • 79
    • 0345689346 scopus 로고    scopus 로고
    • Farnesyltransferase inhibitors in hematologic malignancies: New horizons in therapy
    • Lancet JE, Karp JE. Farnesyltransferase inhibitors in hematologic malignancies: new horizons in therapy. Blood. 2003;102:3880-3889.
    • (2003) Blood , vol.102 , pp. 3880-3889
    • Lancet, J.E.1    Karp, J.E.2
  • 80
    • 79960971028 scopus 로고    scopus 로고
    • FLT3-targeted inhibitors kill FLT3-dependent modeled cells, leukemia-derived cell lines, and primary AML blasts in vitro and in vivo
    • Levis M, Allebach J, Fai-Tse K, et al. FLT3-targeted inhibitors kill FLT3-dependent modeled cells, leukemia-derived cell lines, and primary AML blasts in vitro and in vivo. Blood. 2001;89:721a.
    • (2001) Blood , vol.89 , pp. 721
    • Levis, M.1    Allebach, J.2    Fai-Tse, K.3
  • 81
    • 0036624916 scopus 로고    scopus 로고
    • A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo
    • Levis M, Allebach J, Tse KF, et al. A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo. Blood. 2002;99:3885-3891.
    • (2002) Blood , vol.99 , pp. 3885-3891
    • Levis, M.1    Allebach, J.2    Tse, K.F.3
  • 82
    • 3843142735 scopus 로고    scopus 로고
    • In vitro studies of a FLT3 inhibitor combined with chemotherapy: Sequence of administration is important in order to achieve synergistic cytotoxic effects
    • Levis M, Pham R, Smith BD, Small D. In vitro studies of a FLT3 inhibitor combined with chemotherapy: sequence of administration is important in order to achieve synergistic cytotoxic effects. Blood. 2004;104:1145-1150.
    • (2004) Blood , vol.104 , pp. 1145-1150
    • Levis, M.1    Pham, R.2    Smith, B.D.3    Small, D.4
  • 83
    • 0035437140 scopus 로고    scopus 로고
    • A FLT3 tyrosine kinase inhibitor is selectively cytotoxic to acute myeloid leukemia blasts harboring FLT3 internal tandem duplication mutations
    • Levis M, Tse KF, Smith BD, Garrett E, Small D. A FLT3 tyrosine kinase inhibitor is selectively cytotoxic to acute myeloid leukemia blasts harboring FLT3 internal tandem duplication mutations. Blood. 2001;98:885-887.
    • (2001) Blood , vol.98 , pp. 885-887
    • Levis, M.1    Tse, K.F.2    Smith, B.D.3    Garrett, E.4    Small, D.5
  • 84
    • 32544448534 scopus 로고    scopus 로고
    • K-Ras mutations and N-Ras mutations in childhood acute leukemias with or without mixed-lineage leukemia gene rearrangements
    • Liang DC, Shih LY, Fu JF, et al. K-Ras mutations and N-Ras mutations in childhood acute leukemias with or without mixed-lineage leukemia gene rearrangements. Cancer. 2006;106:950-956.
    • (2006) Cancer. , vol.106 , pp. 950-956
    • Liang, D.C.1    Shih, L.Y.2    Fu, J.F.3
  • 85
    • 13044305857 scopus 로고    scopus 로고
    • Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis
    • Longley BJ, Jr., Metcalfe DD, Tharp M, et al. Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis. Proc Natl Acad Sci USA. 1999;96:1609-1614.
    • (1999) Proc Natl Acad Sci USA. , vol.96 , pp. 1609-1614
    • Longley Jr., B.J.1    Metcalfe, D.D.2    Tharp, M.3
  • 87
    • 33751284416 scopus 로고    scopus 로고
    • Favourable prognosis associated with FLT3 tyrosine kinase domain mutations in AML in contrast to the adverse outcome associated with internal tandem duplications
    • Mead A, Linch D, Hills R, Wheatley K, Burnett A, Gale R. Favourable prognosis associated with FLT3 tyrosine kinase domain mutations in AML in contrast to the adverse outcome associated with internal tandem duplications. Blood. 2005;106:334a.
    • (2005) Blood , vol.106 , pp. 334
    • Mead, A.1    Linch, D.2    Hills, R.3    Wheatley, K.4    Burnett, A.5    Gale, R.6
  • 88
    • 4444369400 scopus 로고    scopus 로고
    • FLT3 internal tandem duplication (FLT3/ITD) is a prognostic factor for poor outcome in pediatric AML: A CCG2961 study
    • Meshinchi S, Alonzo TA, Gerbing R, Lang B, Radich J. FLT3 internal tandem duplication (FLT3/ITD) is a prognostic factor for poor outcome in pediatric AML: a CCG2961 study. Blood. 2003;102:335a.
    • (2003) Blood , vol.102 , pp. 335
    • Meshinchi, S.1    Alonzo, T.A.2    Gerbing, R.3    Lang, B.4    Radich, J.5
  • 89
    • 0041737454 scopus 로고    scopus 로고
    • Activating mutations of RTK/ras signal transduction pathway in pediatric acute myeloid leukemia
    • Meshinchi S, Stirewalt DL, Alonzo TA, et al. Activating mutations of RTK/ras signal transduction pathway in pediatric acute myeloid leukemia. Blood. 2003;102: 1474-1479.
    • (2003) Blood , vol.102 , pp. 1474-1479
    • Meshinchi, S.1    Stirewalt, D.L.2    Alonzo, T.A.3
  • 90
    • 0035168677 scopus 로고    scopus 로고
    • Prevalence and prognostic significance of FLT3 internal tandem duplication in pediatric acute myeloid leukemia
    • Meshinchi S, Woods WG, Stirewalt DL, et al. Prevalence and prognostic significance of FLT3 internal tandem duplication in pediatric acute myeloid leukemia. Blood. 2001;97:89-94.
    • (2001) Blood , vol.97 , pp. 89-94
    • Meshinchi, S.1    Woods, W.G.2    Stirewalt, D.L.3
  • 91
    • 0035412371 scopus 로고    scopus 로고
    • Stable remission after administration of the receptor tyrosine kinase inhibitor SU5416 in a patient with refractory acute myeloid leukemia
    • Mesters RM, Padro T, Bieker R, et al. Stable remission after administration of the receptor tyrosine kinase inhibitor SU5416 in a patient with refractory acute myeloid leukemia. Blood. 2001;98:241-243.
    • (2001) Blood , vol.98 , pp. 241-243
    • Mesters, R.M.1    Padro, T.2    Bieker, R.3
  • 92
    • 0036050018 scopus 로고    scopus 로고
    • Selective apoptosis of tandemly duplicated FLT3-transformed leukemia cells by Hsp90 inhibitors
    • Minami Y, Kiyoi H, Yamamoto Y, et al. Selective apoptosis of tandemly duplicated FLT3-transformed leukemia cells by Hsp90 inhibitors. Leukemia. 2002;16:1535-1540.
    • (2002) Leukemia. , vol.16 , pp. 1535-1540
    • Minami, Y.1    Kiyoi, H.2    Yamamoto, Y.3
  • 93
    • 0141958305 scopus 로고    scopus 로고
    • Different antiapoptotic pathways between wild-type and mutated FLT3: Insights into therapeutic targets in leukemia
    • Minami Y, Yamamoto K, Kiyoi H, Ueda R, Saito H, Naoe T. Different antiapoptotic pathways between wild-type and mutated FLT3: insights into therapeutic targets in leukemia. Blood. 2003;102:2969-2975.
    • (2003) Blood , vol.102 , pp. 2969-2975
    • Minami, Y.1    Yamamoto, K.2    Kiyoi, H.3    Ueda, R.4    Saito, H.5    Naoe, T.6
  • 94
    • 0034554796 scopus 로고    scopus 로고
    • Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways
    • Mizuki M, Fenski R, Halfter H, et al. Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways. Blood. 2000;96:3907-3914.
    • (2000) Blood , vol.96 , pp. 3907-3914
    • Mizuki, M.1    Fenski, R.2    Halfter, H.3
  • 95
    • 0037944120 scopus 로고    scopus 로고
    • Suppression of myeloid transcription factors and induction of STAT response genes by AML-specific Flt3 mutations
    • Mizuki M, Schwable J, Steur C, et al. Suppression of myeloid transcription factors and induction of STAT response genes by AML-specific Flt3 mutations. Blood. 2003;101: 3164-3173.
    • (2003) Blood , vol.101 , pp. 3164-3173
    • Mizuki, M.1    Schwable, J.2    Steur, C.3
  • 96
    • 0037944120 scopus 로고    scopus 로고
    • Suppression of myeloid transcription factors and induction of STAT response genes by AML-specific Flt3 mutations
    • Mizuki M, Schwaeble J, Steur C, et al. Suppression of myeloid transcription factors and induction of STAT response genes by AML-specific Flt3 mutations. Blood. 2003;101(8):3164-3173.
    • (2003) Blood , vol.101 , Issue.8 , pp. 3164-3173
    • Mizuki, M.1    Schwaeble, J.2    Steur, C.3
  • 97
    • 0031132519 scopus 로고    scopus 로고
    • Differential effects of Flk-2/Flt-3 ligand and stem cell factor on murine thymic progenitor cells
    • Moore TA, Zlotnik A. Differential effects of Flk-2/Flt-3 ligand and stem cell factor on murine thymic progenitor cells. J Immunol. 1997;158:4187-4192.
    • (1997) J Immunol. , vol.158 , pp. 4187-4192
    • Moore, T.A.1    Zlotnik, A.2
  • 98
    • 0035869396 scopus 로고    scopus 로고
    • Cell-cycle-dependent activation of mitogen-activated protein kinase kinase (MEK-1/2) in myeloid leukemia cell lines and induction of growth inhibition and apoptosis by inhibitors of RAS signaling
    • Morgan MA, Dolp O, Reuter CW. Cell-cycle-dependent activation of mitogen-activated protein kinase kinase (MEK-1/2) in myeloid leukemia cell lines and induction of growth inhibition and apoptosis by inhibitors of RAS signaling. Blood. 2001;97:1823-1834.
    • (2001) Blood , vol.97 , pp. 1823-1834
    • Morgan, M.A.1    Dolp, O.2    Reuter, C.W.3
  • 99
    • 0033034215 scopus 로고    scopus 로고
    • Thrombopoietin, flt3, and kit ligands together suppress apoptosis of human mobilized CD34+cells and recruit primitive CD34+ Thy-1+ cells into rapid division
    • Murray LJ,Young JC,Osborne LJ, LuensKM, Scollay R, Hill BL. Thrombopoietin, flt3, and kit ligands together suppress apoptosis of human mobilized CD34+cells and recruit primitive CD34+ Thy-1+ cells into rapid division. Exp Hematol. 1999;27:1019-1028.
    • (1999) Exp Hematol. , vol.27 , pp. 1019-1028
    • Murray, L.J.1    Young, J.C.2    Osborne, L.J.3    Luens, K.M.4    Scollay, R.5    Hill, B.L.6
  • 100
    • 0026578668 scopus 로고
    • Multiple point mutation of N-ras andK-ras oncogenes in myelodysplastic syndrome and acute myelogenous leukemia
    • NakagawaT, Saitoh S, Imoto S, et al.Multiple point mutation of N-ras andK-ras oncogenes in myelodysplastic syndrome and acute myelogenous leukemia. Oncology. 1992;49:114-122.
    • (1992) Oncology. , vol.49 , pp. 114-122
    • Nakagawat Saitoh, S.1    Imoto, S.2
  • 101
    • 0030451722 scopus 로고    scopus 로고
    • Internal tandem duplication of the flt3 gene found in acute myeloid leukemia
    • Nakao M, Yokota S, Iwai T, et al. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia. 1996;10:1911-1918.
    • (1996) Leukemia. , vol.10 , pp. 1911-1918
    • Nakao, M.1    Yokota, S.2    Iwai, T.3
  • 102
    • 0030029570 scopus 로고    scopus 로고
    • The FLK2/FLT3 ligand synergizes with interleukin-7 in promoting stromal-cell-independent expansion and differentiation of human fetal pro-B cells in vitro
    • Namikawa R, Muench MO, de Vries JE, Roncarolo MG. The FLK2/FLT3 ligand synergizes with interleukin-7 in promoting stromal-cell-independent expansion and differentiation of human fetal pro-B cells in vitro. Blood. 1996;87:1881-1890.
    • (1996) Blood , vol.87 , pp. 1881-1890
    • Namikawa, R.1    Muench, M.O.2    De Vries, J.E.3    Roncarolo, M.G.4
  • 103
    • 23744498520 scopus 로고    scopus 로고
    • Mutations in the receptor tyrosine kinase pathway are associated with clinical outcome in patients with acute myeloblastic leukemia harboring t(8;21)(q22;q22)
    • Nanri T, Matsuno N, Kawakita T, et al. Mutations in the receptor tyrosine kinase pathway are associated with clinical outcome in patients with acute myeloblastic leukemia harboring t(8;21)(q22;q22). Leukemia. 2005;19:1361-1366.
    • (2005) Leukemia. , vol.19 , pp. 1361-1366
    • Nanri, T.1    Matsuno, N.2    Kawakita, T.3
  • 104
    • 0028214608 scopus 로고
    • Prognostic importance of mutations in the ras proto-oncogenes in de novo acute myeloid leukemia
    • Neubauer A, Dodge RK, George SL, et al. Prognostic importance of mutations in the ras proto-oncogenes in de novo acute myeloid leukemia. Blood. 1994;83:1603-1611.
    • (1994) Blood , vol.83 , pp. 1603-1611
    • Neubauer, A.1    Dodge, R.K.2    George, S.L.3
  • 105
    • 0038204144 scopus 로고    scopus 로고
    • SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo
    • OFarrell AM, Abrams TJ, Yuen HA, et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood. 2003;101:3597-3605.
    • (2003) Blood , vol.101 , pp. 3597-3605
    • Ofarrell, A.M.1    Abrams, T.J.2    Yuen, H.A.3
  • 106
    • 21144451094 scopus 로고    scopus 로고
    • In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants
    • OHare T, Walters DK, Stoffregen EP, et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res. 2005;65:4500-4505.
    • (2005) Cancer Res. , vol.65 , pp. 4500-4505
    • Ohare, T.1    Walters, D.K.2    Stoffregen, E.P.3
  • 107
    • 0033620684 scopus 로고    scopus 로고
    • Farnesyltransferase inhibitors: Targeting the molecular basis of cancer
    • Oliff A. Farnesyltransferase inhibitors: targeting the molecular basis of cancer. Biochimica et Biophysica Acta. 1999;1423:C19-30.
    • (1999) Biochimica et Biophysica Acta. , vol.1423
    • Oliff, A.1
  • 108
    • 33645698808 scopus 로고    scopus 로고
    • Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo
    • Ouyang B, Knauf JA, Smith EP, et al. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo. Clin Cancer Res. 2006;12:1785-1793.
    • (2006) Clin Cancer Res. , vol.12 , pp. 1785-1793
    • Ouyang, B.1    Knauf, J.A.2    Smith, E.P.3
  • 109
    • 17344371122 scopus 로고    scopus 로고
    • RAS FMS and p53 mutations and poor clinical outcome in myelodysplasias: A 10-year follow-up
    • Padua RA, Guinn BA, Al-Sabah AI, et al. RAS, FMS and p53 mutations and poor clinical outcome in myelodysplasias: a 10-year follow-up. Leukemia. 1998;12:887-892.
    • (1998) Leukemia. , vol.12 , pp. 887-892
    • Padua, R.A.1    Guinn, B.A.2    Al-Sabah, A.I.3
  • 110
    • 32944479041 scopus 로고    scopus 로고
    • The Raf inhibitor BAY 43-9006 (Sorafenib) induces caspase-independent apoptosis in melanoma cells
    • Panka DJ, Wang W, Atkins MB, Mier JW. The Raf inhibitor BAY 43-9006 (Sorafenib) induces caspase-independent apoptosis in melanoma cells. Cancer Res. 2006;66:1611-1619.
    • (2006) Cancer Res. , vol.66 , pp. 1611-1619
    • Panka, D.J.1    Wang, W.2    Atkins, M.B.3    Mier, J.W.4
  • 111
    • 0028268635 scopus 로고
    • K-ras and p53 gene mutations in pancreatic cancer: Ductal and nonductal tumors progress through different genetic lesions
    • Pellegata NS, Sessa F, Renault B, et al. K-ras and p53 gene mutations in pancreatic cancer: ductal and nonductal tumors progress through different genetic lesions. Cancer Res. 1994;54:1556-1560.
    • (1994) Cancer Res. , vol.54 , pp. 1556-1560
    • Pellegata, N.S.1    Sessa, F.2    Renault, B.3
  • 112
    • 0028318136 scopus 로고
    • Farnesyltransferase inhibition causes morphological reversion of ras-transformed cells by a complex mechanism that involves regulation of the actin cytoskeleton
    • Prendergast GC, Davide JP, deSolms SJ, et al. Farnesyltransferase inhibition causes morphological reversion of ras-transformed cells by a complex mechanism that involves regulation of the actin cytoskeleton. Mol Cell Biol. 1994;14:4193-4202.
    • (1994) Mol Cell Biol. , vol.14 , pp. 4193-4202
    • Prendergast, G.C.1    Davide, J.P.2    Desolms, S.J.3
  • 113
    • 0024990090 scopus 로고
    • N-ras mutations in adult de novo acute myelogenous leukemia: Prevalence and clinical significance
    • Radich JP, Kopecky KJ, Willman CL, et al. N-ras mutations in adult de novo acute myelogenous leukemia: prevalence and clinical significance. Blood. 1990;76: 801-807.
    • (1990) Blood , vol.76 , pp. 801-807
    • Radich, J.P.1    Kopecky, K.J.2    Willman, C.L.3
  • 114
    • 27444436166 scopus 로고    scopus 로고
    • Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation
    • Rahmani M, Davis EM, Bauer C, Dent P, Grant S. Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation. J Biol Chem. 2005;280:35217-35227.
    • (2005) J Biol Chem. , vol.280 , pp. 35217-35227
    • Rahmani, M.1    Davis, E.M.2    Bauer, C.3    Dent, P.4    Grant, S.5
  • 115
    • 0029957070 scopus 로고    scopus 로고
    • Flt3 ligand supports the differentiation of early B cell progenitors in the presence of interleukin-11 and interleukin
    • Ray RJ, Paige CJ, Furlonger C, Lyman SD, Rottapel R. Flt3 ligand supports the differentiation of early B cell progenitors in the presence of interleukin-11 and interleukin. Eur J Immunol. 1996;26:1504-1510.
    • (1996) Eur J Immunol. , vol.26 , pp. 1504-1510
    • Ray, R.J.1    Paige, C.J.2    Furlonger, C.3    Lyman, S.D.4    Rottapel, R.5
  • 116
    • 33645312560 scopus 로고    scopus 로고
    • Point mutations found in the juxtamembrane domain of FLT3 define a new class of activating mutations in AML
    • Reindl C, Bagrintseva K, Vempati S, et al. Point mutations found in the juxtamembrane domain of FLT3 define a new class of activating mutations in AML. Blood. 2006.
    • (2006) Blood
    • Reindl, C.1    Bagrintseva, K.2    Vempati, S.3
  • 119
    • 9144253166 scopus 로고    scopus 로고
    • Prognostic significance of N-RAS and K-RAS mutations in 232 patients with acute myeloid leukemia
    • Ritter M, Kim TD, Lisske P, Thiede C, Schaich M, Neubauer A. Prognostic significance of N-RAS and K-RAS mutations in 232 patients with acute myeloid leukemia. Haematologica. 2004;89:1397-1399.
    • (2004) Haematologica. , vol.89 , pp. 1397-1399
    • Ritter, M.1    Kim, T.D.2    Lisske, P.3    Thiede, C.4    Schaich, M.5    Neubauer, A.6
  • 120
    • 0034693799 scopus 로고    scopus 로고
    • The protein tyrosine kinase family of the human genome
    • Robinson DR, Wu YM, Lin SF. The protein tyrosine kinase family of the human genome. Oncogene. 2000;19:5548-5557.
    • (2000) Oncogene. , vol.19 , pp. 5548-5557
    • Robinson, D.R.1    Wu, Y.M.2    Lin, S.F.3
  • 122
    • 2642519463 scopus 로고    scopus 로고
    • Acute myeloid leukemia induced by graded reduction of a lineage-specific transcription factor PU.1
    • Rosenbauer F, Wagner K, Kutok JL, et al. Acute myeloid leukemia induced by graded reduction of a lineage-specific transcription factor, PU.1. Nat Genet. 2004;36:624-630.
    • (2004) Nat Genet. , vol.36 , pp. 624-630
    • Rosenbauer, F.1    Wagner, K.2    Kutok, J.L.3
  • 123
    • 27744551009 scopus 로고    scopus 로고
    • Structure and regulation of Kit protein-tyrosine kinase-The stem cell factor receptor
    • Roskoski R, Jr. Structure and regulation of Kit protein-tyrosine kinase-the stem cell factor receptor. Biochem Biophys Res Commun. 2005;338:1307-1315.
    • (2005) Biochem Biophys Res Commun. , vol.338 , pp. 1307-1315
    • Roskoski Jr., R.1
  • 124
    • 0027130517 scopus 로고
    • Hematopoietic receptors of class III receptor-type tyrosine kinases
    • Rosnet O, Birnbaum D. Hematopoietic receptors of class III receptor-type tyrosine kinases. Crit Rev Oncog. 1993;4:595-613.
    • (1993) Crit Rev Oncog. , vol.4 , pp. 595-613
    • Rosnet, O.1    Birnbaum, D.2
  • 125
    • 0024272031 scopus 로고
    • A point mutation in the extracellular domain of the human CSF-1 receptor (c-fms proto-oncogene product) activates its transforming potential
    • Roussel MF, Downing JR, Rettenmier CW, Sherr CJ. A point mutation in the extracellular domain of the human CSF-1 receptor (c-fms proto-oncogene product) activates its transforming potential. Cell. 1988;55:979-988.
    • (1988) Cell. , vol.55 , pp. 979-988
    • Roussel, M.F.1    Downing, J.R.2    Rettenmier, C.W.3    Sherr, C.J.4
  • 126
    • 0030059543 scopus 로고    scopus 로고
    • The FLT3 ligand is a direct and potent stimulator of the growth of primitive and committed human CD34+ bone marrow progenitor cells in vitro
    • Rusten LS, Lyman SD, Veiby OP, Jacobsen SE. The FLT3 ligand is a direct and potent stimulator of the growth of primitive and committed human CD34+ bone marrow progenitor cells in vitro. Blood. 1996;87:1317-1325.
    • (1996) Blood , vol.87 , pp. 1317-1325
    • Rusten, L.S.1    Lyman, S.D.2    Veiby, O.P.3    Jacobsen, S.E.4
  • 127
    • 23644454231 scopus 로고    scopus 로고
    • The AML1-ETO fusion gene and the FLT3 length mutation collaborate in inducing acute leukemia in mice
    • Schessl C, Rawat VP, Cusan M, et al. The AML1-ETO fusion gene and the FLT3 length mutation collaborate in inducing acute leukemia in mice. J Clin Invest. 2005;115: 2159-2168.
    • (2005) J Clin Invest. , vol.115 , pp. 2159-2168
    • Schessl, C.1    Rawat, V.P.2    Cusan, M.3
  • 128
    • 31544459272 scopus 로고    scopus 로고
    • Dasatinib (BMS-354825), a dual SRC/ ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies
    • Schittenhelm MM, Shiraga S, Schroeder A, et al. Dasatinib (BMS-354825), a dual SRC/ ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res. 2006;66:473-481.
    • (2006) Cancer Res. , vol.66 , pp. 473-481
    • Schittenhelm, M.M.1    Shiraga, S.2    Schroeder, A.3
  • 129
    • 33344465478 scopus 로고    scopus 로고
    • KIT-D816 mutations in AML1-ETOpositive AML are associated with impaired event-free and overall survival
    • Schnittger S, Kohl TM, Haferlach T, et al. KIT-D816 mutations in AML1-ETOpositive AML are associated with impaired event-free and overall survival. Blood. 2006;107: 1791-1799.
    • (2006) Blood , vol.107 , pp. 1791-1799
    • Schnittger, S.1    Kohl, T.M.2    Haferlach, T.3
  • 130
    • 0036659931 scopus 로고    scopus 로고
    • Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: Correlation to cytogenetics FAB subtype and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease
    • Schnittger S, Schoch C, Dugas M, et al. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood. 2002;100:59-66.
    • (2002) Blood , vol.100 , pp. 59-66
    • Schnittger, S.1    Schoch, C.2    Dugas, M.3
  • 131
    • 1342331479 scopus 로고    scopus 로고
    • Opinion: Searching for the elusive targets of farnesyltransferase inhibitors
    • Sebti SM, Der CJ. Opinion: searching for the elusive targets of farnesyltransferase inhibitors. Nat Rev Cancer. 2003;3:945-951.
    • (2003) Nat Rev Cancer. , vol.3 , pp. 945-951
    • Sebti, S.M.1    Der, C.J.2
  • 132
    • 67650584040 scopus 로고    scopus 로고
    • National Cancer Institute; 2004 Accessed on 15 July
    • SEER Cancer Statistics Review 1975-2001, Vol.2004. National Cancer Institute; 2004. http://seer.cancer.gov/csr/1975-2004/. Accessed on 15 July, 2009.
    • (2009) SEER Cancer Statistics Review 1975-2001 , vol.2004
  • 133
    • 0030005639 scopus 로고    scopus 로고
    • Flt3 ligand induces proliferation of quiescent human bone marrow CD34+CD38- cells and maintains progenitor cells in vitro
    • Shah AJ, Smogorzewska EM, Hannum C, Crooks GM. Flt3 ligand induces proliferation of quiescent human bone marrow CD34+CD38- cells and maintains progenitor cells in vitro. Blood. 1996;87:3563-3570.
    • (1996) Blood , vol.87 , pp. 3563-3570
    • Shah, A.J.1    Smogorzewska, E.M.2    Hannum, C.3    Crooks, G.M.4
  • 134
    • 33344471932 scopus 로고    scopus 로고
    • KIT mutations, and not FLT3 internal tandem duplication, are strongly associated with a poor prognosis in pediatric acute myeloid leukemia with t(8;21): A study of the Japanese Childhood AML Cooperative Study Group
    • Shimada A, Taki T, Tabuchi K, et al. KIT mutations, and not FLT3 internal tandem duplication, are strongly associated with a poor prognosis in pediatric acute myeloid leukemia with t(8;21): a study of the Japanese Childhood AML Cooperative Study Group. Blood. 2006;107:1806-1809.
    • (2006) Blood , vol.107 , pp. 1806-1809
    • Shimada, A.1    Taki, T.2    Tabuchi, K.3
  • 135
    • 0025074419 scopus 로고
    • K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung
    • Slebos RJ, Kibbelaar RE, Dalesio O, et al. K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N Engl J Med. 1990;323:561-565.
    • (1990) N Engl J Med. , vol.323 , pp. 561-565
    • Slebos, R.J.1    Kibbelaar, R.E.2    Dalesio, O.3
  • 136
    • 1842420032 scopus 로고    scopus 로고
    • Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia
    • Smith BD, Levis M, Beran M, et al. Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. Blood. 2004;103:3669-3676.
    • (2004) Blood , vol.103 , pp. 3669-3676
    • Smith, B.D.1    Levis, M.2    Beran, M.3
  • 137
    • 0141500350 scopus 로고    scopus 로고
    • Single agent CEP-701, a novel FLT-3 inhibitor, shows initial response in patients with refractory acute myeloid leukemia
    • Smith BD, Levis M, Brown P, et al. Single agent CEP-701, a novel FLT-3 inhibitor, shows initial response in patients with refractory acute myeloid leukemia. Blood. 2002;100:314a.
    • (2002) Blood , vol.100 , pp. 314
    • Smith, B.D.1    Levis, M.2    Brown, P.3
  • 138
    • 0037266198 scopus 로고    scopus 로고
    • Mutation of BRAF is uncommon in AML FAB type M1 and M2
    • Smith ML, Snadden J, Neat M, et al. Mutation of BRAF is uncommon in AML FAB type M1 and M2. Leukemia. 2003;17:274-275.
    • (2003) Leukemia. , vol.17 , pp. 274-275
    • Smith, M.L.1    Snadden, J.2    Neat, M.3
  • 139
    • 0035282940 scopus 로고    scopus 로고
    • The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF receptor (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts
    • Smolich BD, Yuen HA, West KA, Giles FJ, Albitar M, Cherrington JM. The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF receptor (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts. Blood. 2001;97:1413-1421.
    • (2001) Blood , vol.97 , pp. 1413-1421
    • Smolich, B.D.1    Yuen, H.A.2    West, K.A.3    Giles, F.J.4    Albitar, M.5    Cherrington, J.M.6
  • 140
    • 0036839326 scopus 로고    scopus 로고
    • A new and recurrent activating length mutation in exon 20 of the FLT3 gene in acute myeloid leukemia
    • Spiekermann K, Bagrintseva K, Schoch C, Haferlach T, Hiddemann W, Schnittger S. A new and recurrent activating length mutation in exon 20 of the FLT3 gene in acute myeloid leukemia. Blood. 2002;100:3423-3425.
    • (2002) Blood , vol.100 , pp. 3423-3425
    • Spiekermann, K.1    Bagrintseva, K.2    Schoch, C.3    Haferlach, T.4    Hiddemann, W.5    Schnittger, S.6
  • 142
    • 18044387648 scopus 로고    scopus 로고
    • Raf kinase as a target for anticancer therapeutics
    • Sridhar SS, Hedley D, Siu LL. Raf kinase as a target for anticancer therapeutics. Mol Cancer Ther. 2005;4:677-685.
    • (2005) Mol Cancer Ther. , vol.4 , pp. 677-685
    • Sridhar, S.S.1    Hedley, D.2    Siu, L.L.3
  • 144
    • 0035383768 scopus 로고    scopus 로고
    • FLT3 RAS and TP53 mutations in elderly patients with acute myeloid leukemia
    • Stirewalt DL, Kopecky KJ, Meshinchi S, et al. FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia. Blood. 2001;97:3589-3595.
    • (2001) Blood , vol.97 , pp. 3589-3595
    • Stirewalt, D.L.1    Kopecky, K.J.2    Meshinchi, S.3
  • 145
    • 33646431111 scopus 로고    scopus 로고
    • Size of FLT3 internal tandem duplication has prognostic significance in patients with acute myeloid leukemia
    • Stirewalt DL, Kopecky KJ, Meshinchi S, et al. Size of FLT3 internal tandem duplication has prognostic significance in patients with acute myeloid leukemia. Blood. 2006;107: 3724-3726.
    • (2006) Blood , vol.107 , pp. 3724-3726
    • Stirewalt, D.L.1    Kopecky, K.J.2    Meshinchi, S.3
  • 146
    • 1242315428 scopus 로고    scopus 로고
    • Novel FLT3 point mutations within exon 14 found in patients with acute myeloid leukaemia
    • Stirewalt DL, Meshinchi S, Kussick SJ, et al. Novel FLT3 point mutations within exon 14 found in patients with acute myeloid leukaemia. Br J Haematol. 2004;124:481-484.
    • (2004) Br J Haematol. , vol.124 , pp. 481-484
    • Stirewalt, D.L.1    Meshinchi, S.2    Kussick, S.J.3
  • 147
    • 0141465061 scopus 로고    scopus 로고
    • The role of FLT3 in haematopoietic malignancies
    • Stirewalt DL, Radich JP. The role of FLT3 in haematopoietic malignancies. Nat Rev Cancer. 2003;3:650-665.
    • (2003) Nat Rev Cancer. , vol.3 , pp. 650-665
    • Stirewalt, D.L.1    Radich, J.P.2
  • 148
    • 19944427559 scopus 로고    scopus 로고
    • Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor PKC412
    • Stone RM, DeAngelo DJ, Klimek V, et al. Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood. 2005;105:54-60.
    • (2005) Blood , vol.105 , pp. 54-60
    • Stone, R.M.1    Deangelo, D.J.2    Klimek, V.3
  • 149
    • 33747378382 scopus 로고    scopus 로고
    • Phase 1B study of PKC412, an oral FLT3 kinase inhibitor, in sequential and simultaneous combinations with daunorubicin and cytarabine (DA) induction and high-dose consolidation in newly diagnosed patients with AML
    • Stone RM, Fischer T, Paquette R, et al. Phase 1B study of PKC412, an oral FLT3 kinase inhibitor, in sequential and simultaneous combinations with daunorubicin and cytarabine (DA) induction and high-dose consolidation in newly diagnosed patients with AML. Blood. 2005;106:404a.
    • (2005) Blood , vol.106 , pp. 404
    • Stone, R.M.1    Fischer, T.2    Paquette, R.3
  • 150
    • 0012774179 scopus 로고    scopus 로고
    • PKC412, an oral FLT3 inhibitor, has activity inmutant FLT3 acute myeloid leukemia (AML): A phase II clinical trial
    • StoneRM,Klimek V, J.DD, et al. PKC412, an oral FLT3 inhibitor, has activity inmutant FLT3 acute myeloid leukemia (AML): a phase II clinical trial. Blood. 2002;100:316a.
    • (2002) Blood , vol.100 , pp. 316
    • Stonermklimek, V.1    J, D.D.2
  • 151
    • 20844439887 scopus 로고    scopus 로고
    • Somatic PTPN11 mutations in childhood acute myeloid leukaemia
    • Tartaglia M, Martinelli S, Iavarone I, et al. Somatic PTPN11 mutations in childhood acute myeloid leukaemia. Br J Haematol. 2005;129:333-339.
    • (2005) Br J Haematol. , vol.129 , pp. 333-339
    • Tartaglia, M.1    Martinelli, S.2    Iavarone, I.3
  • 152
    • 0037097716 scopus 로고    scopus 로고
    • Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: Association with FAB subtypes and identification of subgroups with poor prognosis
    • Thiede C, Steudel C, Mohr B, et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood. 2002;99:4326-4335.
    • (2002) Blood , vol.99 , pp. 4326-4335
    • Thiede, C.1    Steudel, C.2    Mohr, B.3
  • 153
    • 0025276780 scopus 로고
    • Mutation of the human FMS gene (M-CSF receptor) in myelodysplastic syndromes and acute myeloid leukemia
    • Tobal K, Pagliuca A, Bhatt B, Bailey N, Layton DM, Mufti GJ. Mutation of the human FMS gene (M-CSF receptor) in myelodysplastic syndromes and acute myeloid leukemia. Leukemia. 1990;4:486-489.
    • (1990) Leukemia. , vol.4 , pp. 486-489
    • Tobal, K.1    Pagliuca, A.2    Bhatt, B.3    Bailey, N.4    Layton, D.M.5    Mufti, G.J.6
  • 154
    • 0033999917 scopus 로고    scopus 로고
    • Fatal myeloproliferation, induced in mice by TEL/PDGFbetaR expression, depends on PDGFbetaR tyrosines 579/581
    • Tomasson MH, Sternberg DW, Williams IR, et al. Fatal myeloproliferation, induced in mice by TEL/PDGFbetaR expression, depends on PDGFbetaR tyrosines 579/581. J Clin Invest. 2000;105:423-432.
    • (2000) J Clin Invest. , vol.105 , pp. 423-432
    • Tomasson, M.H.1    Sternberg, D.W.2    Williams, I.R.3
  • 155
    • 0033084227 scopus 로고    scopus 로고
    • TEL/PDGFbetaR induces hematologic malignancies in mice that respond to a specific tyrosine kinase inhibitor
    • Tomasson MH, Williams IR, Hasserjian R, et al. TEL/PDGFbetaR induces hematologic malignancies in mice that respond to a specific tyrosine kinase inhibitor. Blood. 1999;93:1707-1714.
    • (1999) Blood , vol.93 , pp. 1707-1714
    • Tomasson, M.H.1    Williams, I.R.2    Hasserjian, R.3
  • 156
    • 33646468642 scopus 로고    scopus 로고
    • Pharmacodynamic monitoring of BAY 43-9006 (Sorafenib) in phase i clinical trials involving solid tumor and AML/MDS patients, using flow cytometry to monitor activation of the ERK pathway in peripheral blood cells
    • Tong FK, Chow S, Hedley D. Pharmacodynamic monitoring of BAY 43-9006 (Sorafenib) in phase I clinical trials involving solid tumor and AML/MDS patients, using flow cytometry to monitor activation of the ERK pathway in peripheral blood cells. Cytometry B Clin Cytom. 2006;70(3):107-114.
    • (2006) Cytometry B Clin Cytom. , vol.70 , Issue.3 , pp. 107-114
    • Tong, F.K.1    Chow, S.2    Hedley, D.3
  • 157
    • 0030972025 scopus 로고    scopus 로고
    • Constitutive activation of mitogen-activated protein kinase pathway in acute leukemia cells
    • Towatari M, Iida H, Tanimoto M, Iwata H, Hamaguchi M, Saito H. Constitutive activation of mitogen-activated protein kinase pathway in acute leukemia cells. Leukemia. 1997;11:479-484.
    • (1997) Leukemia. , vol.11 , pp. 479-484
    • Towatari, M.1    Iida, H.2    Tanimoto, M.3    Iwata, H.4    Hamaguchi, M.5    Saito, H.6
  • 158
    • 0036799356 scopus 로고    scopus 로고
    • Inhibition of the transforming activity of FLT3 internal tandem duplication mutants from AML patients by a tyrosine kinase inhibitor
    • Tse KF, Allebach J, Levis M, Smith BD, Bohmer FD, Small D. Inhibition of the transforming activity of FLT3 internal tandem duplication mutants from AML patients by a tyrosine kinase inhibitor. Leukemia. 2002;16:2027-2036.
    • (2002) Leukemia. , vol.16 , pp. 2027-2036
    • Tse, K.F.1    Allebach, J.2    Levis, M.3    Smith, B.D.4    Bohmer, F.D.5    Small, D.6
  • 159
    • 0033820091 scopus 로고    scopus 로고
    • Constitutive activation of FLT3 stimulates multiple intracellular signal transducers and results in transformation
    • Tse KF, Mukherjee G, Small D. Constitutive activation of FLT3 stimulates multiple intracellular signal transducers and results in transformation. Leukemia. 2000;14: 1766-1776.
    • (2000) Leukemia. , vol.14 , pp. 1766-1776
    • Tse, K.F.1    Mukherjee, G.2    Small, D.3
  • 160
    • 0028229976 scopus 로고
    • Ligand-independent activation of c-kit receptor tyrosine kinase in a murine mastocytoma cell line P-815 generated by a point mutation
    • Tsujimura T, Furitsu T, Morimoto M, et al. Ligand-independent activation of c-kit receptor tyrosine kinase in a murine mastocytoma cell line P-815 generated by a point mutation. Blood. 1994;83:2619-2626.
    • (1994) Blood , vol.83 , pp. 2619-2626
    • Tsujimura, T.1    Furitsu, T.2    Morimoto, M.3
  • 161
    • 0030816204 scopus 로고    scopus 로고
    • Mechanisms of constitutive activation of c-kit receptor tyrosine kinase
    • Tsujimura T, Kanakura Y, Kitamura Y. Mechanisms of constitutive activation of c-kit receptor tyrosine kinase. Leukemia. 1997;11 Suppl 3:396-398.
    • (1997) Leukemia. , vol.11 , Issue.SUPPL 3 , pp. 396-398
    • Tsujimura, T.1    Kanakura, Y.2    Kitamura, Y.3
  • 162
    • 0030032943 scopus 로고    scopus 로고
    • Constitutive activation of c-kit in FMA3 murine mastocytoma cells caused by deletion of seven amino acids at the juxtamembrane domain
    • Tsujimura T, Morimoto M, Hashimoto K, et al. Constitutive activation of c-kit in FMA3 murine mastocytoma cells caused by deletion of seven amino acids at the juxtamembrane domain. Blood. 1996;87:273-283.
    • (1996) Blood , vol.87 , pp. 273-283
    • Tsujimura, T.1    Morimoto, M.2    Hashimoto, K.3
  • 163
    • 0029998037 scopus 로고    scopus 로고
    • FLT3 receptor expression on the surface of normal and malignant human hematopoietic cells
    • Turner AM, Lin NL, Issarachai S, Lyman SD, Broudy VC. FLT3 receptor expression on the surface of normal and malignant human hematopoietic cells. Blood. 1996;88: 3383-3390.
    • (1996) Blood , vol.88 , pp. 3383-3390
    • Turner, A.M.1    Lin, N.L.2    Issarachai, S.3    Lyman, S.D.4    Broudy, V.C.5
  • 164
    • 18544398712 scopus 로고    scopus 로고
    • Constitutive activation of c-kit by the juxtamembrane but not the catalytic domain mutations is inhibited selectively by tyrosine kinase inhibitors STI571 and AG1296
    • Ueda S, Ikeda H, Mizuki M, et al. Constitutive activation of c-kit by the juxtamembrane but not the catalytic domain mutations is inhibited selectively by tyrosine kinase inhibitors STI571 and AG1296. Int J Hematol. 2002;76:427-435.
    • (2002) Int J Hematol. , vol.76 , pp. 427-435
    • Ueda, S.1    Ikeda, H.2    Mizuki, M.3
  • 165
    • 0025289924 scopus 로고
    • Identification of tyrosine 706 in the kinase insert as the major colony-stimulating factor 1 (CSF-1)-stimulated autophosphorylation site in the
    • van der Geer P, Hunter T. Identification of tyrosine 706 in the kinase insert as the major colony-stimulating factor 1 (CSF-1)-stimulated autophosphorylation site in the CSF-1 receptor in a murine macrophage cell line. Mol Cell Biol. 1990;10:2991-3002.
    • (1990) Mol Cell Biol. , vol.10 , pp. 2991-3002
    • Van Der Geer, P.1    Hunter, T.2
  • 166
    • 3042678647 scopus 로고    scopus 로고
    • Clinical and molecular features of FIP1L1-PDFGRA (+) chronic eosinophilic leukemias
    • Vandenberghe P, Wlodarska I, Michaux L, et al. Clinical and molecular features of FIP1L1-PDFGRA (+) chronic eosinophilic leukemias. Leukemia. 2004;18:734-742.
    • (2004) Leukemia. , vol.18 , pp. 734-742
    • Vandenberghe, P.1    Wlodarska, I.2    Michaux, L.3
  • 167
    • 0029793903 scopus 로고    scopus 로고
    • Combined signaling through interleukin-7 receptors and flt3 but not c-kit potently and selectively promotes B-cell commitment and differentiation from uncommitted murine bone marrow progenitor cells
    • Veiby OP, Lyman SD, Jacobsen SE. Combined signaling through interleukin-7 receptors and flt3 but not c-kit potently and selectively promotes B-cell commitment and differentiation from uncommitted murine bone marrow progenitor cells. Blood. 1996;88: 1256-1265.
    • (1996) Blood , vol.88 , pp. 1256-1265
    • Veiby, O.P.1    Lyman, S.D.2    Jacobsen, S.E.3
  • 168
    • 0024994577 scopus 로고
    • RAS gene mutations in childhood acute myeloid leukemia: A Pediatric Oncology Group study
    • Vogelstein B, Civin CI, Preisinger AC, et al. RAS gene mutations in childhood acute myeloid leukemia: a Pediatric Oncology Group study. Genes Chromosomes Cancer. 1990;2:159-162.
    • (1990) Genes Chromosomes Cancer. , vol.2 , pp. 159-162
    • Vogelstein, B.1    Civin, C.I.2    Preisinger, A.C.3
  • 169
    • 31544446922 scopus 로고    scopus 로고
    • Potent and selective mitogen-activated protein kinase kinase (MEK) 1,2 inhibitors. 1. 4-(4-bromo-2-fluorophenylamino)-1-methylpyridin-2(1H)-ones
    • Wallace EM, Lyssikatos J, Blake JF, et al. Potent and selective mitogen-activated protein kinase kinase (MEK) 1,2 inhibitors. 1. 4-(4-bromo-2-fluorophenylamino)-1-methylpyridin-2(1H)-ones. J Med Chem. 2006;49:441-444.
    • (2006) J Med Chem. , vol.49 , pp. 441-444
    • Wallace, E.M.1    Lyssikatos, J.2    Blake, J.F.3
  • 170
    • 19944431253 scopus 로고    scopus 로고
    • AML1-ETO and C-KIT mutation/overexpression in t(8;21) leukemia: Implication in stepwise leukemogenesis and response to Gleevec
    • Wang YY, Zhou GB, Yin T, et al. AML1-ETO and C-KIT mutation/ overexpression in t(8;21) leukemia: implication in stepwise leukemogenesis and response to Gleevec. Proc Natl Acad Sci USA. 2005;102:1104-1109.
    • (2005) Proc Natl Acad Sci USA. , vol.102 , pp. 1104-1109
    • Wang, Y.Y.1    Zhou, G.B.2    Yin, T.3
  • 171
    • 0033915130 scopus 로고    scopus 로고
    • Growth factor receptor tyrosine kinases: Cell adhesion kinase family suggests a novel signaling mechanism in cancer
    • Weiner HL, Zagzag D. Growth factor receptor tyrosine kinases: cell adhesion kinase family suggests a novel signaling mechanism in cancer. Cancer Invest. 2000;18:544-554.
    • (2000) Cancer Invest. , vol.18 , pp. 544-554
    • Weiner, H.L.1    Zagzag, D.2
  • 172
    • 0036595143 scopus 로고    scopus 로고
    • Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412
    • Weisberg E, Boulton C, Kelly LM, et al. Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. Cancer Cell. 2002;1:433-443.
    • (2002) Cancer Cell. , vol.1 , pp. 433-443
    • Weisberg, E.1    Boulton, C.2    Kelly, L.M.3
  • 173
    • 0035476264 scopus 로고    scopus 로고
    • Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: A cancer and leukemia group B study
    • Whitman SP, Archer KJ, Feng L, et al. Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study. Cancer Res. 2001;61:7233-7239.
    • (2001) Cancer Res. , vol.61 , pp. 7233-7239
    • Whitman, S.P.1    Archer, K.J.2    Feng, L.3
  • 174
    • 0029928615 scopus 로고    scopus 로고
    • Transfection of human ovarian cancer cells with the HER-2/neu receptor tyrosine kinase induces a selective increase in PTP-H1, PTP-1B, PTP-alpha expression
    • Wiener JR, Kassim SK, Yu Y, Mills GB, Bast RC, Jr. Transfection of human ovarian cancer cells with the HER-2/neu receptor tyrosine kinase induces a selective increase in PTP-H1, PTP-1B, PTP-alpha expression. Gynecol Oncol. 1996;61:233-240.
    • (1996) Gynecol Oncol. , vol.61 , pp. 233-240
    • Wiener, J.R.1    Kassim, S.K.2    Yu, Y.3    Mills, G.B.4    Bast Jr., R.C.5
  • 175
    • 0035871889 scopus 로고    scopus 로고
    • Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies
    • Yamamoto Y, Kiyoi H, Nakano Y, et al. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood. 2001;97:2434-2439.
    • (2001) Blood , vol.97 , pp. 2434-2439
    • Yamamoto, Y.1    Kiyoi, H.2    Nakano, Y.3
  • 176
    • 33644807219 scopus 로고    scopus 로고
    • Haploinsufficiency of Runx1/AML1 promotes myeloid features and leukaemogenesis in BXH2 mice
    • Yamashita N, Osato M, Huang L, et al. Haploinsufficiency of Runx1/AML1 promotes myeloid features and leukaemogenesis in BXH2 mice. Br J Haematol. 2005;131:495-507.
    • (2005) Br J Haematol. , vol.131 , pp. 495-507
    • Yamashita, N.1    Osato, M.2    Huang, L.3
  • 177
    • 0037108298 scopus 로고    scopus 로고
    • SU5416 and SU5614 inhibit kinase activity of wild-type and mutant FLT3 receptor tyrosine kinase
    • Yee KW, OFarrell AM, Smolich BD, et al. SU5416 and SU5614 inhibit kinase activity of wild-type and mutant FLT3 receptor tyrosine kinase. Blood. 2002;100:2941-2949.
    • (2002) Blood , vol.100 , pp. 2941-2949
    • Yee, K.W.1    Ofarrell, A.M.2    Smolich, B.D.3
  • 178
    • 0027157536 scopus 로고
    • Mechanism of kit ligand, phorbol ester, and calciuminduced down-regulation of c-kit receptors in mast cells
    • Yee NS, Langen H, Besmer P. Mechanism of kit ligand, phorbol ester, and calciuminduced down-regulation of c-kit receptors in mast cells. J Biol Chem. 1993;268:14189-14201.
    • (1993) J Biol Chem. , vol.268 , pp. 14189-14201
    • Yee, N.S.1    Langen, H.2    Besmer, P.3
  • 179
    • 16944365287 scopus 로고    scopus 로고
    • Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines
    • Yokota S, Kiyoi H, Nakao M, et al. Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines. Leukemia. 1997;11:1605-1609.
    • (1997) Leukemia. , vol.11 , pp. 1605-1609
    • Yokota, S.1    Kiyoi, H.2    Nakao, M.3
  • 180
    • 0034093724 scopus 로고    scopus 로고
    • In vivo treatment of mutant FLT3-transformed murine leukemia with a tyrosine kinase inhibitor
    • Zhao M, Kiyoi H, Yamamoto Y, et al. In vivo treatment of mutant FLT3-transformed murine leukemia with a tyrosine kinase inhibitor. Leukemia. 2000;14:374-378.
    • (2000) Leukemia. , vol.14 , pp. 374-378
    • Zhao, M.1    Kiyoi, H.2    Yamamoto, Y.3
  • 181
    • 9144269029 scopus 로고    scopus 로고
    • FLT3 ligand causes autocrine signaling in acute myeloid leukemia cells
    • Zheng R, Levis M, Piloto O, et al. FLT3 ligand causes autocrine signaling in acute myeloid leukemia cells. Blood. 2004;103:267-274.
    • (2004) Blood , vol.103 , pp. 267-274
    • Zheng, R.1    Levis, M.2    Piloto, O.3
  • 182
    • 0141482006 scopus 로고    scopus 로고
    • FLT3 internal tandem duplication in 234 children with acute myeloid leukemia: Prognostic significance and relation to cellular drug resistance
    • Zwaan CM, Meshinchi S, Radich JP, et al. FLT3 internal tandem duplication in 234 children with acute myeloid leukemia: prognostic significance and relation to cellular drug resistance. Blood. 2003;102:2387-2394.
    • (2003) Blood , vol.102 , pp. 2387-2394
    • Zwaan, C.M.1    Meshinchi, S.2    Radich, J.P.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.